Open AccessP524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3‐MUTATED R/R AML (KB‐LANRA 1001)
Author(s) -
Stein E. M.,
Patel A.,
Michaelis L. C.,
Schiller G.,
Swords R.,
Carvajal L. A.,
Bray G.,
DiMartino J.,
Levy M. Y.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844984.10616.3d
Subject(s) - syk , midostaurin , medicine , pharmacology , myeloid leukemia , tyrosine kinase inhibitor , tolerability , tyrosine kinase , cancer research , fms like tyrosine kinase 3 , myeloid , adverse effect , chemistry , receptor , cancer , biochemistry , mutation , gene